Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1983 1
1985 1
1986 2
1987 1
1989 2
1991 2
1992 2
1993 6
1994 4
1995 4
1996 7
1997 8
1998 5
1999 6
2000 4
2001 15
2002 13
2003 16
2004 13
2005 29
2006 14
2007 13
2008 12
2009 15
2010 12
2011 14
2012 15
2013 14
2014 14
2015 11
2016 7
2017 5
2018 7
2019 3
2020 5
2021 8
2022 9
2023 1
2024 1

Text availability

Article attribute

Article type

Publication date

Search Results

288 results

Results by year

Filters applied: . Clear all
Page 1
Tolvaptan in patients with autosomal dominant polycystic kidney disease.
Torres VE, Chapman AB, Devuyst O, Gansevoort RT, Grantham JJ, Higashihara E, Perrone RD, Krasa HB, Ouyang J, Czerwiec FS; TEMPO 3:4 Trial Investigators. Torres VE, et al. N Engl J Med. 2012 Dec 20;367(25):2407-18. doi: 10.1056/NEJMoa1205511. Epub 2012 Nov 3. N Engl J Med. 2012. PMID: 23121377 Free PMC article. Clinical Trial.
Revised equations for estimated GFR from serum creatinine in Japan.
Matsuo S, Imai E, Horio M, Yasuda Y, Tomita K, Nitta K, Yamagata K, Tomino Y, Yokoyama H, Hishida A; Collaborators developing the Japanese equation for estimated GFR. Matsuo S, et al. Am J Kidney Dis. 2009 Jun;53(6):982-92. doi: 10.1053/j.ajkd.2008.12.034. Epub 2009 Apr 1. Am J Kidney Dis. 2009. PMID: 19339088
Initiation of renin-angiotensin system inhibitors and first complete remission in patients with primary nephrotic syndrome: a nationwide cohort study.
Shimizu S, Niihata K, Nishiwaki H, Shibagaki Y, Yamamoto R, Nitta K, Tsukamoto T, Uchida S, Takeda A, Okada H, Narita I, Isaka Y, Kurita N; Japan Nephrotic Syndrome Cohort Study Group. Shimizu S, et al. Clin Exp Nephrol. 2023 May;27(5):480-489. doi: 10.1007/s10157-023-02331-3. Epub 2023 Feb 25. Clin Exp Nephrol. 2023. PMID: 36840902
Atherogenic lipoproteins in end-stage renal disease.
Shoji T, Ishimura E, Inaba M, Tabata T, Nishizawa Y. Shoji T, et al. Among authors: ishimura e. Am J Kidney Dis. 2001 Oct;38(4 Suppl 1):S30-3. doi: 10.1053/ajkd.2001.27393. Am J Kidney Dis. 2001. PMID: 11576918 Review.
Acute Kidney Injury and Remission of Proteinuria in Minimal Change Disease.
Yamamoto R, Imai E, Maruyama S, Yokoyama H, Sugiyama H, Takeda A, Uchida S, Tsukamoto T, Tsuruya K, Akai Y, Nitta K, Fukunaga M, Hayashi H, Shoji T, Masutani K, Konta T, Katafuchi R, Nishio S, Wada T, Goto S, Tamai H, Shirasaki A, Nagai K, Nishino T, Yamagata K, Kazama JJ, Hiromura K, Yasuda H, Sofue T, Fujimoto S, Mizutani M, Naruse T, Hiramatsu T, Morozumi K, Sobajima H, Saka Y, Ishimura E, Ito T, Ichikawa D, Shigematsu T, Sato H, Narita I, Yoshitaka I; Japan Nephrotic Syndrome Cohort Study investigators. Yamamoto R, et al. Among authors: ishimura e. Kidney Int Rep. 2022 Aug 5;7(10):2283-2288. doi: 10.1016/j.ekir.2022.07.173. eCollection 2022 Oct. Kidney Int Rep. 2022. PMID: 36217532 Free PMC article. No abstract available.
The Efficacy of Low-Density Lipoprotein Apheresis in a Patient with Drug-Resistant Minimal Change Nephrotic Syndrome: A Case Report and A Review of the Literature.
Nakatani S, Ishimura E, Okute Y, Nakatani A, Uedono H, Tsuda A, Naganuma T, Takemoto Y, Mori K, Emoto M, Inaba M. Nakatani S, et al. Among authors: ishimura e. Nephrology (Carlton). 2018 Jun;23(6):603-604. doi: 10.1111/nep.13120. Nephrology (Carlton). 2018. PMID: 29890046 Review. No abstract available.
288 results